This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Men's Health  • Prostate Disease  • Oncology  • Prostate Cancer  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2009;301(17):1753-1754.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A new guideline calls for physicians who screen asymptomatic men for prostate cancer to advise them about a multiyear regimen of medication that may reduce their risk of developing the disease. But the guideline also states that current evidence suggests the medication offers no benefit in reducing prostate cancer mortality or overall mortality. Nor does it dismiss the possibility that the drug might actually increase the risk of getting a higher-grade, and more deadly, form of this cancer.

The guideline, issued February 24 by an expert panel jointly convened by the American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA), focuses on men with a prostate-specific antigen (PSA) level of 3.0 ng/mL or less who are regularly screened with a PSA test or who are considering receiving an annual PSA test. Physicians are directed to tell these patients that they may benefit from taking a . . . [Full Text of this Article]

AVOIDING TREATMENT



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?